SG11201407184PA - Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals - Google Patents

Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals

Info

Publication number
SG11201407184PA
SG11201407184PA SG11201407184PA SG11201407184PA SG11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA
Authority
SG
Singapore
Prior art keywords
international
pharmaceuticals
preparing
derivatives
chromen
Prior art date
Application number
SG11201407184PA
Other languages
English (en)
Inventor
Jayaraman Venkat Raman
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407184P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of SG11201407184PA publication Critical patent/SG11201407184PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
SG11201407184PA 2012-05-04 2013-05-03 Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals SG11201407184PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1737CH2012 2012-05-04
US201261671956P 2012-07-16 2012-07-16
PCT/IB2013/053544 WO2013164801A1 (en) 2012-05-04 2013-05-03 Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals

Publications (1)

Publication Number Publication Date
SG11201407184PA true SG11201407184PA (en) 2014-12-30

Family

ID=54193684

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407184PA SG11201407184PA (en) 2012-05-04 2013-05-03 Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals

Country Status (25)

Country Link
US (1) US9309216B2 (zh)
EP (1) EP2844647B1 (zh)
JP (2) JP6290186B2 (zh)
KR (1) KR102073181B1 (zh)
CN (2) CN108084138A (zh)
AP (1) AP3547A (zh)
AU (1) AU2013255469B2 (zh)
BR (1) BR112014027470A2 (zh)
CA (1) CA2871000C (zh)
CL (1) CL2014002986A1 (zh)
CO (1) CO7141413A2 (zh)
CY (1) CY1123456T1 (zh)
EA (1) EA032812B1 (zh)
HK (1) HK1203964A1 (zh)
IL (1) IL235181A (zh)
MX (1) MX365250B (zh)
MY (1) MY171207A (zh)
NZ (1) NZ701198A (zh)
PH (1) PH12014502453A1 (zh)
PL (1) PL2844647T3 (zh)
RS (1) RS61035B1 (zh)
SG (1) SG11201407184PA (zh)
SI (1) SI2844647T1 (zh)
WO (1) WO2013164801A1 (zh)
ZA (1) ZA201407769B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2496567T3 (pl) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
US10130635B2 (en) * 2012-05-04 2018-11-20 Rhizen Pharmaceuticals Sa Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
EA032812B1 (ru) * 2012-05-04 2019-07-31 Ризен Фармасьютикалз Са Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов
BR112015030385B1 (pt) 2013-06-07 2020-08-18 Rhizen Pharmaceuticals S.A. Composto, composto para uso e composição farmacêutica
CA2951370A1 (en) * 2014-06-27 2015-12-30 Rhizen Pharmaceuticals Sa Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3325462A4 (en) * 2015-07-23 2019-06-19 Pharmakea, Inc. INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS
JP2019508400A (ja) 2016-02-09 2019-03-28 ファーマケア,インク. キノリノンリシルオキシダーゼ様2阻害剤とその使用
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
PL2496567T3 (pl) * 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
SG194718A1 (en) * 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
EA032812B1 (ru) * 2012-05-04 2019-07-31 Ризен Фармасьютикалз Са Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов
ES2647416T3 (es) * 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Inhibidores de PI3K delta selectivos

Also Published As

Publication number Publication date
JP6290186B2 (ja) 2018-03-07
NZ701198A (en) 2016-09-30
HK1203964A1 (zh) 2015-11-06
CA2871000C (en) 2021-10-19
AU2013255469B2 (en) 2017-10-12
ZA201407769B (en) 2016-05-25
WO2013164801A1 (en) 2013-11-07
PL2844647T3 (pl) 2021-01-25
CO7141413A2 (es) 2014-12-12
KR20150006876A (ko) 2015-01-19
CN104507922B (zh) 2018-02-09
EP2844647A1 (en) 2015-03-11
PH12014502453B1 (en) 2015-03-16
BR112014027470A2 (pt) 2017-06-27
AP2014008087A0 (en) 2014-11-30
EA201491818A1 (ru) 2015-04-30
RS61035B1 (sr) 2020-12-31
CA2871000A1 (en) 2013-11-07
JP2015515975A (ja) 2015-06-04
MX2014013426A (es) 2015-05-11
AU2013255469A1 (en) 2014-11-13
CL2014002986A1 (es) 2015-01-09
US20150087699A1 (en) 2015-03-26
EP2844647B1 (en) 2020-07-22
KR102073181B1 (ko) 2020-02-04
US9309216B2 (en) 2016-04-12
EA032812B1 (ru) 2019-07-31
CN108084138A (zh) 2018-05-29
MX365250B (es) 2019-05-28
MY171207A (en) 2019-10-02
CN104507922A (zh) 2015-04-08
AP3547A (en) 2016-01-14
PH12014502453A1 (en) 2015-03-16
SI2844647T1 (sl) 2020-12-31
IL235181A (en) 2017-12-31
JP2018039849A (ja) 2018-03-15
CY1123456T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201408261UA (en) Syringe
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201909011PA (en) Niraparib compositions
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407934UA (en) Camsylate salt